COMMUNIQUÉS West-GlobeNewswire
-
R1 Expands Phare OS with Phare UM, Bringing Real-Time Payer Risk Intelligence to Utilization Management
16/09/2026 -
Syneos Health and Tufts CSDD Study Shows Clinical Trial Performance Depends More on Operating Model Design Than Sourcing Strategy
16/09/2026 -
Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
16/09/2026 -
Seer Surpasses 100 Peer-Reviewed Customer Publications, Validating a New Era of Deep Proteomics at Scale
16/09/2026 -
Novo and Anthropic will collaborate to advance drug discovery with Claude
16/09/2026 -
Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care
16/09/2026 -
Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum
16/09/2026 -
Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders’ Equity Requirement
16/09/2026 -
Stereotaxis Emerging Digital, AI and Automation Capabilities to be Featured at Heart Rhythm Society’s HRX 2026
16/09/2026 -
ESA Letter in Utah: RealESALetter.com Gains Recognition Among Utah Residents
16/09/2026 -
Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®
16/09/2026 -
Abalos Therapeutics Publishes Two Articles in Viruses Further Validating its AdaptInnate Approach to Treat Solid Tumors
16/09/2026 -
Theolytics to Showcase its Innovative Oncolytic Immunotherapy Strategy – including THEO-260 in Advanced Ovarian Cancer – at Upcoming Investor and Scientific Events
16/09/2026 -
EIB and Angelini Ventures’ Partnership Reaches €48.5 Million in Investments
16/09/2026 -
UpFront Diagnostics Announces CE Mark Approval for LVOne — the World's First Rapid Blood Test to Diagnose Stroke
16/09/2026 -
UpFront Diagnostics obtient le marquage CE pour LVOne, premier test sanguin rapide au monde destiné au diagnostic de l’AVC
16/09/2026 -
Novo to share real-world and clinical data including Wegovy® pill, and cardiometabolic pipeline progress with next-generation amylin treatments at EASD 2026
16/09/2026 -
EURETINA: PulseSight Therapeutics to Present Results of Phase 1 clinical trial of PST-611 treatment for dry AMD/Geographic Atrophy (GA)
16/09/2026 -
First Patient In - BioPorto Initiates Patient Enrollment as part of the ProNephro AKI® U.S. Adult Urine NGAL Validation Study.
16/09/2026
Pages